ReNeuron
| Public company | |
| Traded as | LSE: RENE |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
| Website | reneuron.com |
ReNeuron is a UK-based stem cell research company, whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem cell therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases.
ReNeuron is currently testing the effects of neural stem cells on spines for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]
See also
References
- ↑ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- ↑ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
External links
This article is issued from Wikipedia - version of the Saturday, February 14, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.